The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

Background Interleukin 2 receptor antagonists (IL2Ra) are used as induction therapy for
prophylaxis against acute rejection in kidney transplant recipients. Use of IL2Ra has …

Wide variations in tacrolimus levels have been identified as a risk factor for inferior kidney
allograft survival but past studies have not properly accounted for the dynamic nature of drug …

Identifying effective treatment combinations for MS patients failing standard therapy is an
important goal. We report the results of a phase II open label baseline-to-treatment trial of a …

Nondepleting anti-CD25 monoclonal antibodies (daclizumab) and depleting polyclonal
antithymocyte globulin (Thymoglobulin) both prevent acute rejection, but these therapies …

The evolution of immunosuppression for organ transplantation has reduced the incidence of
acute graft rejection but has increased the risk for infection and virally mediated malignancie …

Antilymphocyte therapies are widely used for immunosuppression in solid organ
transplantation. These agents have varied mechanisms of action, with resulting differences …

Immunosuppression strategies that selectively inhibit effector T cells while preserving and
even enhancing CD4+FOXP3+ regulatory T cells (Treg) permit immune self-regulation and …

Currently available immunosuppressive agents can be classified into three categories:
induction agents, maintenance therapy, and treatment for rejection. This review article will …

Campath-1H (Alemtuzumab) is an effective immunodepletion agent used in renal
transplantation. To evaluate its influence on T lymphocytes during repletion, we analyzed …